Sunitinib Intake Conditions in the Treatment of Patients With Renal Cell Carcinoma

Cancer Foundation, China

Status: Completed

Conditions: Renal Cell Carcinoma

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT01441661

CFC20110815

Details and patient eligibility

About

This non-interventional study includes patients with advanced renal cell carcinoma who are treated with Sunitinib alone or combined with other systemic therapies. The aim of the trial is to increase knowledge about usage, dosage, efficacy and safety under conditions of routine use of Sunitinib.

Full description

Because State Food and Drug Administration (SFDA) exempted manufacturers from conducting clinical trials of Sunitinib in China, overall efficacy and safety data of Sunitinib in Chinese patients with renal cell carcinoma were deficiency. The investigators carried out this research project will be sufficient evidence, and help clinicians in China to make decision in real daily practice.

Enrollment: 400 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically or cytologically confirmed, unresectable advanced renal cell carcinoma;
• Sunitinib as first-line treatment alone or combined with other therapies.

Exclusion criteria

• History of Grade 3/4 severe allergic reaction to Sunitinib or its metabolites

Trial design

400 participants in 1 patient group

Sunitinib Renal Cell Carcinoma

Description:

Patients diagnosed with Renal Cell Carcinoma (RCC) and treated with Sunitinib from 2008 to present will be eligible. This will include current active patients as well as patients who have expired and have medical records available.